re: morphosys news I note that Lanthio already had licensed their lead compound out, meaning that they must have done a fair bit of pre-clinical development work (not just pulling out "hits"). This may well be why Morphosys did the deal, as Lanthio had already proved their peptides make good drug candidates. Other than PYC35 for burns etc, PYC has never really done that to the degree that pharma require.
re: morphosys news I note that Lanthio already had licensed...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.38 |
Change
-0.013(0.90%) |
Mkt cap ! $804.8M | |||
| Open | High | Low | Value | Volume |
| $1.39 | $1.43 | $1.37 | $142.5K | 102.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1142 | $1.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.39 | 1504 | 3 |
View Market Depth
| Last trade - 15.17pm 15/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |